Determination of the level of fgf-9 gene expression in serum samples of patients with lung cancer

Lung cancer is one of the major causes of cancer deaths. The activation of fgf signals, including fgf-9, is involved in the pathogenesis of several cancers, including lung cancer. Also, fgf-9 may be an indicator for prognosis and is associated with survival rates in patients with NSCLC. Therefore, in this study, the rate of fgf-9 gene expression in the serum patients with lung cancer was investigated. Analysis

In this study, 50 serum samples of healthy subjects and 50 serum samples of NSCLC patients were collected from patients referring to Masih Daneshvari Hospital in Tehran and were collected by questionnaires, individual and clinical data of the subjects. Then, Plasma isolation, RNA extraction, cDNA synthesis, primer design were performed and the rate of changes of fgf-9 expression in the serum of healthy and lung cancer patients was evaluated using Real Time PCR. REST software was used to analyze the results.

In this study, the expression of fgf-9 gene was not significantly different in the serum of patients with the first to third stages of metastasis but in the serum of people with stage IV metastasis the level of expression of fgf-9 gene had a significant reduction of 4.46 (p < 0.05) times than normal samples.

According to the results of this study, if these results are confirmed in more samples, the level of the fgf-9 gene expression in the serum of individuals can probably be used in the future to predict the stage of metastasis of lung cancer